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Objective: White blood cells are known to predict cardiovascular mortality, but form a highly hetero-
geneous population. It is therefore possible that speciﬁc subtypes disproportionally contribute to the
prediction of cardiovascular outcomes. Therefore, we compared leukocyte subsets alone and in
conjunction with an established inﬂammatory marker, C-reactive protein, for predicting death due to
cardiovascular disease in a high-risk population.
Methods: Patients, 3316, (mean [SD] age, 62 [10] years) scheduled for coronary angiography were
prospectively followed up. Neutrophil, monocyte and lymphocyte counts were determined. Neutrophil
and monocyte subsets were further analysed on the basis of surface expression of CD11b, CD18, CD31,
CD40 and CD58. Lymphocytes were further subdivided into CD3, CD4, CD8, and CD19 subsets. The
association between each marker and subsequent cardiovascular mortality was assessed using multi-
variable Cox regression models.
Results: During a median follow-up period of 7.8 years, 745 (22.5%) patients died, of which 484 were due
to cardiovascular events. After entering conventional risk factors and removing patients with a current
infection, neutrophil count (HR [95% CI]¼ 1.90 [1.39, 2.60], P< 0.001) and the neutrophil/lymphocyte
ratio (HR [95% CI]¼ 1.68 [1.24, 2.27], P¼ 0.003) emerged as independent predictors of cardiovascular
mortality. After mutual adjustment, neutrophil count (HR [95% CI]¼ 1.87 [1.35, 2.50], P< 0.001) out-
performed C-reactive protein (HR [95% CI] 1.32 [0.99, 1.78], P¼ 0.06) as a predictor of cardiovascular
mortality.
Conclusions: Due to its predictive potential and inexpensive determination, assessment of high neutro-
phil counts may represent an important marker, possibly improving cardiovascular mortality risk
prediction.
 2012 Published by Elsevier Ireland Ltd.1. Introduction
A modest but consistent relationship between the white blood
cell (WBC) count and cardiovascular disease (CVD) has beenPublic Health, Social and
Mannheim Medical Faculty,
1 20 525 6506.
Elsevier Ireland Ltd.reported in several epidemiologic studies [1e3], and these obser-
vations are in line with the role of leukocytes in atherosclerosis
[4,5]. WBCs are however, a very heterogeneous population of cells,
and more recent studies have begun to evaluate the predictive
utility of speciﬁc WBC subsets. For example, in one prospective
study of patients with acute myocardial infarction (MI), Dragu et al.
[6] reported that, of the three main leukocytes subsets (i.e.,
neutrophils, monocytes, and lymphocytes), elevated neutrophils
best correlated with mortality. Likewise, in a secondary sample of
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greatest prediction for coronary artery disease (CAD) was provided
by neutrophils and the neutrophil/lymphocyte ratio. The neutro-
phil/lymphocyte ratio was also found to be a strong predictor of
long-term mortality in patients who underwent percutaneous
coronary intervention (PCI) and in patients who were admitted for
ST segment elevation MI (STEMI) [8,9].
Moving forward, there are further important distinctions
between functionally distinct immune cells. Within the lympho-
cyte compartment, these include T-helper cells (CD4), T-cytotoxic
cells (CD8), B cells (CD19) and Natural Killer cells (CD16/CD56).
These sub-populations greatly differ in functionality and propor-
tions, in which they are present in the atheromata [10,11] and the
same holds true for monocyte subtypes [12]. Nonetheless, very
little is known concerning the interplay between these subsets and
CVD. Further, the limited data on such subsets have seldom eval-
uated their predictive utility independent of validated inﬂamma-
tory markers such as C-reactive protein (CRP) [13].
In light of the preceding comments, the present study was
undertaken to investigate the predictive ability of the total WBC
count and its differential subsets with CVD mortality. Further, we
sought to determine whether these associations, if any, were
independent of the well-established inﬂammatory marker, CRP.
Lastly, we examined whether these ﬁndings would remain robust
after controlling for the potential confounding effects of infection.2. Methods
2.1. Participants and setting
Data reported in this paper come from the LUdwigshafen RIsk
and Cardiovascular Health (LURIC) study, which is an ongoing
prospective cohort study designed to investigate environmental
and genetic risk factors for CVD [14]. Of the 3358 subjects enrolled
in the LURIC study, 18 (0.5%) patients were lost during follow-up.
Another 24 (0.7%) study participants were excluded because we
did not obtain sufﬁcient data. Hence, the analytic sample included
a total of 3316 subjects (2309 men and 1007 women), 18e95 years.
Baseline examination was performed between July 1997 and
January 2000 in a single tertiary care medical centre in South-West
Germany (Herzzentrum, Ludwigshafen). Inclusion criteria were
availability of a coronary angiogram, Caucasians of German
ancestry to limit genetic heterogeneity, and clinical stability, with
the exception of acute coronary syndromes (ACS). ACS presentation
included a stable pattern of chest pain (i.e. stable angina pectoris)
or an unstable pattern of chest pain, suggesting unstable angina
pectoris. Participants with a history of malignancy within the past
ﬁve years, or any predominant non-cardiac disease were excluded
from the study. The LURIC study was approved by the institutional
review board of the ethics committee at the “Landesärztekammer
Rheinland-Pfalz” (Mainz, Germany) and written informed consent
was obtained from all study participants.2.2. Study endpoint
Information on vital status was obtained from local community
registries. The primary endpoint in this study was death due to
CVD. Death certiﬁcates were reviewed to classify the deceased into
thosewho died from cardiovascular and non-cardiovascular events.
Death from cardiovascular causes included sudden cardiac death
(SCD), fatal MI, death due to heart failure, death after intervention
to treat CAD, stroke and other deaths due to heart disease. Two
experienced physicians that were blinded to any data of the study
probands except for the information from the death certiﬁcatesindependently classiﬁed the causes of death. In the case of
a disagreement concerning the classiﬁcation, it was discussed and
the ﬁnal decision was made by one of the principal investigators of
LURIC (W.M.), who was also blinded to any data except the death
certiﬁcates.
2.3. Biochemical measurements
Sampling of fasted venous blood occurred in the early morning,
and was always performed in the supine position. Haematological
laboratory parameters were immediately measured on a daily basis
as previously mentioned [14]. Total WBC and differential counts
were determined using EDTA whole blood and were later quanti-
ﬁed using an automated analyser (Technicon H-1, Bad Vilbel,
Germany; until Dec 1998/Advia 120, Bayer Diagnostics, Tarrytown,
USA; since Jan 1999). Glucose was determined using the enzymatic
hexokinase/glucose 6-phosphate dehydrogenase method (GLU
Hitachi 717, Roche Mannheim, Germany). Lipids (i.e., total choles-
terol, LDL- and HDL-cholesterol, and triglycerides) were measured
with enzymatic reagents from WAKO (Neuss, Germany) and lipo-
proteins were separated with a combined ultracentrifugation and
precipitation method as described [14]. High-sensitivity C-reactive
protein (hs-CRP) was measured by immunonephelometry (N
LATEX CRP mono from Dade Behring, Marburg, Germany).
2.4. Flow cytometry
Leukocytes were prepared using a whole blood lyse no-wash
method, according to manufacturer recommendations (Bectone
Dickinson). Preparations were analysed on a four-color ﬂow
cytometer (FACSCalibur, BectoneDickinson) at the Institute of
Haematology and Transfusion Medicine of the Ludwigshafen
General Hospital using routine methods. In brief, main leukocyte
subsets (neutrophils, monocytes, lymphocytes) were identiﬁed by
forward vs side-scatter; whereby CD14 expression was used to
further validate separation of monocytes and neutrophils [15].
Mean ﬂuorescence intensity (MFI) of the neutrophil and monocyte
compartments was assessed for the surface markers CD11b, CD18,
CD31, CD40 and CD58 on cells. Within the lymphocyte compart-
ment CD3, CD4, CD8, CD16/CD56 and CD19 surface markers were
used to identify main lymphocyte subsets (cytotoxic T cells, helper
T cells, Natural Killer [NK] cells, and B cells), as described previously
[16,17]. All ﬂuorescent-labelled antibodies were purchased from
BectoneDickinson (Heidelberg, Germany), with the exception of
CD40, which was purchased from DiaClone (Besacon, France).
2.5. Other variables measured
The LURIC baseline examination has been described in detail
elsewhere [14]. Brieﬂy, all body measures were obtained and
recorded by trained nurses belonging to the LURIC study team.
Resting heart rate was obtained during the morning by electro-
cardiography. Five measures were taken 30 s apart, following
a 10 min rest in the supine position, with the average derived from
the last two measures. Brachial artery pressure values were
measured with an automated oscillometric device (Hamburg,
Germany) after the patient had rested in the supine position for
10 min. At least ﬁve consecutive measures of systolic and diastolic
blood pressures were taken with a minimum interval of 30 s, with
the average obtained from the last two. Arterial hypertension was
diagnosed if mean systolic or diastolic blood pressures exceeded
140/90 mmHg or if there was a clinically signiﬁcant history of
hypertension. Body mass was measured using a Tanita body
composition analyser (Tanita corp., Japan). Dyslipidaemia was
deﬁned if total cholesterol was 6.2 mmol/L, HDL-cholesterol was
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or use of lipid-lowering medication. Diabetes mellitus was diag-
nosed if fasting glucose was> 7.0 mmol/L or the 2 h value from an
oral glucose tolerance test was> 11.1 mmol/L. Patients receiving
anti-diabetic medication were also classed as being diabetic.
Family history of CVD was self-reported when a ﬁrst-degree
relative had suffered either fatal or non-fatal MI or stroke (<55
years in father or other ﬁrst-degree male relative, or <65 years in
mother or other ﬁrst-degree female relative). The functional
capacity for patients with cardiac disease, especially heart failure,
was estimated according to a classiﬁcation developed by the New
York Heart Association (NYHA) [14]. Coronary angiography
allowed for disease severity to be determined. The angiographic
severity of disease was deﬁned as zero-, one-, two- or three-vessel
disease based on the number of luminal narrowing’s 50% in the
three major coronary arteries. Self-reported data were available on
the diagnosis of infections (e.g., “At this time have you been
diagnosed with an ongoing infection”? Possible answers were
“yes” or “no”), permitting us to remove subjects who reported
having an infection and who may have spuriously contributed to
the observed inﬂammatory state, or number of deaths due to CVD
mortality [18e20]. Rather than simply exclude patients with
a WBC count above the clinically deﬁned normal range, this
approach may, in part, eliminate the potential contributions from
other infections that may not have caused the WBC count to rise
above the normal range.
2.6. Statistical methods
Continuous parameters following a non-normal distribution
underwent a natural logarithmic transformation (base e logarithm)
before being used in statistical procedures. We also calculated z-
values of logarithmically transformed total WBC and differential
compartments based on their mean and SD values (formula for z-
values; x e mean/SD). Exploratory analyses also revealed a curvi-
linear association between lymphocytes and CVD mortality. Upon
removal of the CD16/CD56 subset, a normal-linear distribution was
restored. For the purpose of this investigation, lymphocyte count
excluding the CD16/CD56 sub-population was used during anal-
yses. After standardisation, total and differential WBC compart-
ments were split into quartiles. Categorical data are reported as
percentages and depending on their distribution, continuous data
are presented as means with SD values (normal distribution) or as
geometric means with 95% conﬁdence intervals (95% CI) (skewed
distribution). Comparisons between groups were performed by
analysis of variance (ANOVA), with P for linear trend for continuous
parameters and c2 test with P for linear-by-linear test for categor-
ical variables. KaplaneMeier survival function with Log-rank test
for equality was used to evaluate the predictive ability of baseline
total and differential WBC counts with cardiovascular mortality.
Time-to-event analyses were performed using univariable and
multivariable Cox proportional hazard models. Multivariable
analyses were adjusted for a range of conventional risk factors (e.g.,
age, sex, BMI, smoking, type 2 diabetes mellitus, resting heart rate,
systolic and diastolic blood pressure, hypertension, dyslipidaemia,
and angina pectoris), clinical indication of coronary angiography,
symptoms of heart failure, CAD severity, atrial ﬁbrillation, family
history of CVD, percutaneous transluminal coronary angioplasty,
cardiovascular treatment (i.e., ACE-inhibitors, angiotensin receptor
blockers, b-blockers, statins and aspirin) and hs-CRP. Additional
sensitivity analysis removed patients with a current infection
(n¼ 318) who may have spuriously contributed towards the risk of
death due to CVD. All statistical tests were two-tailed, and statis-
tical signiﬁcance was deﬁned as P< 0.05. Calculations were per-
formed using the SPSS software version 18.0 (SPSS Inc., Chicago, IL,USA) and STATA software version 11.2 (Stata Corp., College Station,
TX, USA).
3. Results
3.1. Study population
The study population consisted of 3316 patients referred for
coronary angiography with a median follow-up time of 7.8 years. Of
these patients, 745 (22.5%) had died due to either a non-CVD event
(n¼ 261) or a CVD event (n¼ 484) (Table 1). Those who suffered an
event were older and predominantly male (Table 1). Compared to
the other groups, current infections, hs-CRP, glucose and preva-
lence of type 2 diabetes mellitus were all higher among patients
who had died as a result of CVD (Table 1). Total and HDL-cholesterol
levels were lower in those who had died during the follow-up as
compared to those who had survived (Table 1). Also, resting heart
rate, systolic blood pressure and arterial hypertension were
signiﬁcantly higher among those who had died as compared to
survivors (Table 1). Patients who had suffered a CVD event reported
more severe symptoms of heart failure as compared to the other
categories (Table 1). Likewise, the prevalence in the number of
diseased vessels and cardiac arrhythmias was higher among these
patients (Table 1).
3.2. Baseline WBC counts
We subsequently examined the predictive value of baseline total
and differential WBC counts with CVD mortality using
KaplaneMeier survival function. Log-rank tests revealed a signiﬁ-
cant association between total and differential WBCs with CVD
mortality. For example, patients in the highest quartile for total
WBCs, monocytes, or neutrophils had a lower cumulative survival,
while patients in the lowest quartile for lymphocytes had a lower
cumulative survival (P< 0.001, Fig. 1).
3.3. Univariable and multivariable analyses
In univariable analyses, the risk for CVDmorality increased with
increasing levels of total WBCs, neutrophils, monocytes, neutro-
phil/lymphocyte ratio and monocyte/lymphocyte ratio, while
mortality decreased with lymphocytes (Table 2). Further analyses
of the neutrophil, monocyte and lymphocyte compartments
revealed a reduced risk for CVD mortality according to CD3, CD4,
and CD19 lymphocytes, CD31 neutrophils and an increased risk for
CD58 monocytes (Table 3). Entering conventional risk factors,
symptoms of heart failure, CAD severity, family history of CVD and
medical therapy partly attenuated the associations found for total
WBC, neutrophil, monocyte and lymphocyte counts and neutro-
phil/lymphocyte and monocyte/lymphocyte ratios (Table 2).
After removing patients with a current infection, we found the
test for trend no longer remained signiﬁcant for total WBC,
monocyte, lymphocyte, counts as well as the individual compart-
ments (Tables 2 and 3). Although the HR across each quartile for
monocyte/lymphocyte ratio diminished, a signiﬁcant albeit modest
trend remained (Table 2). In contrast, the neutrophil count and
neutrophil/lymphocyte ratio were retained as independent
predictors of CVD death (Table 2).
To better understand the relationship between neutrophils and
CVD mortality, we repeated the latter analyses including only
patients with stable CAD (n¼ 2232). After comparing the upper-
most quartile to the lowest, the fully adjusted association
between the neutrophil count and CVD mortality remained virtu-
ally identical, HR (95% CI)¼ 1.93 (1.39, 2.67), P< 0.001. We then
performed the analyses including only individuals with ACS
Table 1
Demographic characteristics of patients.
Characteristic No event n¼ 2571 Non–CVD event n¼ 261 CVD event n¼ 484 P valuea
Age 61 11 69 9* 68 9* <0.001
Male (%) 68.3 74.7 74.2 0.003
BMI (kg/m2) 27.5 4.0 26.9 4.6 27.3 4.3 0.06
Current smoker (%) 20.6 18.8 15.7 0.64
Current infection (%) 9.2 8.8 12.4 0.04
High-sensitivity C-reactive protein (mg/L) 7.87 (7.22 8.51) 12.69 (10.03, 15.35)* 13.21 (11.19, 15.23)* <0.001
Glucose (mmol/L) 5.24 (5.12, 5.30) 5.58 (5.38, 5.80)* 5.93 (5.76, 6.10)* 0.003
Type 2 diabetes mellitus (%) 13.1 24.9 35.3 <0.001
Blood lipids (mmol/L)
Triglycerides 1.70 (1.67, 1.74) 1.71 (1.61, 1.81) 1.69 (1.62, 1.77) 0.94
Total cholesterol 4.90 (4.86, 4.94) 4.76 (4.65, 4.88) 4.76 (4.67, 4.85)* 0.003
LDL-cholesterol 2.89 (2.85, 2.92) 2.80 (2.69, 2.91) 2.83 (2.75, 2.91) 0.15
HDL-cholesterol 0.97 (0.96, 0.98) 0.94 (0.91, 0.97) 0.90 (0.88, 0.93)* <0.001
Dyslipidaemia (%) 68.7 69.3 70.2 0.49
Resting heart rate (bpm) 68 11 70 12 71 13 <0.001
Blood pressure (mmHg)
Systolic 139 (138, 140) 146 (143, 149)* 144 (142, 147)* <0.001
Diastolic 81 (80, 81) 80 (79, 81) 80 (79, 81) 0.33
Arterial hypertension (%) 51.1 62.8 59.1 <0.001
New York Heart Association functional class (%)
1 56.2 37.5 37.0 <0.001
2 28.9 31.4 29.5
3 12.8 25.7 27.1
4 2.1 5.4 6.4
Diseased vessels (%)
0 35.1 24.3 17.5 <0.001
1 19.1 18.5 18.4
2 19.1 19.3 18.8
3 26.7 37.8 45.4
Coronary angiography (%) 98.6 99.2 97.9 0.45
Unstable angina pectoris (%) 32.5 33.6 24.6 <0.001
Atrial ﬁbrillation (%) 10.3 12.1 21.9 <0.001
Family history of CVD (%) 54.1 44.1 46.3 <0.001
Percutaneous transluminal coronary angioplasty (%) 26.3 29.5 24.6 0.31
Cardiovascular medication use (%)
ACE-inhibitors 49.9 62.1 67.1 <0.001
ARBs 4.2 4.2 6.4 0.03
b-blockers 65.7 58.6 53.1 <0.001
Statins 47.7 43.7 44.2 0.10
Aspirin 71.3 73.2 71.4 0.39
Continuous data are shown as means SD or geometric mean (95% conﬁdence intervals) and categorical data are shown as percentages.
a ANOVA and c2 test were used. *P< 0.05 when compared to non-event; yP< 0.05 when compared to non-CVD event. CVD¼ cardiovascular disease; BMI¼ body mass
index; LDL¼ low density lipoprotein; HDL¼ high density lipoprotein; ACE¼ angiotensin converting enzyme; ARB¼ angiotensin receptor blocker.
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for CVD mortality according to the highest quartile of the neutro-
phil count, HR (95% CI)¼ 2.32 (1.32, 4.06), P¼ 0.003.
We compared the predictive value of a high neutrophil count
with an established inﬂammatory marker (hs-CRP). Following
mutual adjustment, we found both were independently associated
with death due to CVD (Fig. 2). After entering conventional risk
factors, neutrophils remained essentially unchanged whereas hs-
CRP attenuated by almost 60% (Fig. 2). Lastly, after excluding
those who reported a current infection, the neutrophil count
remained a strong independent predictor of CVD mortality, while
the reliability of hs-CRP was largely weakened (Fig. 2).3.4. Additional analysis
We employed a multivariable Cox proportional hazard model
using competing risks methods as described by Jason and Gray
[21] to obtain more accurate and reliable estimates for the risk of
CVD mortality according to a higher neutrophil count. This anal-
ysis took into consideration a competing risk event (i.e. death due
to a non-CVD related cause) which may have otherwise impeded
the event of interest (CVD mortality). Though after full adjustment
we observed a slight attenuation in the risk, neutrophils in theupper-most quartile remained strongly associated with death
due to CVD, HR (95% CI)¼ 1.54 (1.16, 2.03), P¼ 0.01 (data not
shown).3.5. Discrimination, reclassiﬁcation and calibration
Based on the conventional risk factors, we employed a backward
regression procedure using competing risks methodology to
determine the best risk-estimation model (Table 4). We then
computed the c-statistic and the area under the receiving operating
characteristic (AUC) curve to compare the conventional risk model
with a model based on a combination of the retained traditional
risk factors and the neutrophil count. The results are shown in
Fig. 3. Here, the conventional model had already obtained a high
discrimination, with a c-statistic of 0.767. In comparison, adding the
neutrophil count only marginally improved discrimination (0.776,
P¼ 0.04). However, due to the known discriminatory limitations of
the c-statistic and AUC, we also computed the reclassiﬁcation
statistics of integrated discrimination improvement (IDI) and net
reclassiﬁcation improvement (NRI) [22]. When the IDI was
considered, inclusion of the neutrophil count achieved a signiﬁcant
improvement in model discrimination (0.012, P< 0.001). For the
NRI, we chose a priori meaningful risk category of <6, 6e20, and
Fig. 1. KaplaneMeier plots for cardiovascular mortality according to the numbers of total white blood cells (WBC) (P¼ 0.001, Log-rank test), lymphocyte (P< 0.001), monocyte
(P< 0.001), and neutrophil (P< 0.001) quartiles. Lymphocte count excluded CD16/CD56 sub-population.
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Third Adult Treatment Panel (ATP III) risk classiﬁcation [23]. Here,
adding the neutrophil count to the conventional risk model resul-
ted in correct reclassiﬁcation of an individual to a different risk
category by 5% (P¼ 0.003, Table 5). Lastly, model calibration using
the HosmereLemeshow goodness-of-ﬁt test yielded a chi-square of
7.62 (P¼ 0.47), indicating no signiﬁcant deviation between pre-
dicted and observed risk (Fig. 4).
4. Discussion
The present study investigated the predictive utility of leukocyte
subsets in an intermediate to high-risk population. One of the main
ﬁndings was that, of all leukocyte subsets assessed, a neutrophil
count in the upper 25% (>7.3103/ml) emerged as the strongestpredictor for CVD mortality, yielding an almost two-fold increased
adjusted risk of death. This association showed only modest
attenuation after correcting for an extensive number of established
risk markers.
Comparative analysis between neutrophils and hs-CRP, which
is the most commonly measured inﬂammatory marker in cardio-
vascular epidemiology, indicated that the neutrophil count is
a more robust predictor (both in terms of effect size and stability)
in this population. Speciﬁcally, the HR for hs-CRP steadily declined
with incremental adjustment, and became non-signiﬁcant when
patients who reported a current infection (e.g., a current cold,
hepatitis B) were removed from the model. Indeed, the low
robustness of CRP has been addressed by other authors [24,25].
Further convincing evidence proposes that CRP may well be a non-
causal factor of CVD mortality. A recent meta-analysis of 18
Table 2
Hazard ratios (with 95% CIs) for cardiovascular mortality according to total and differential white blood cell counts.
Quartiles
1st 2nd 3rd 4th P for trend
Total WBC counta 5.86 (5.81, 5.90) 7.20 (7.18, 7.22) 8.37 (8.34, 8.40) 10.66 (10.57, 10.75)
No. of study participants at risk 829 824 825 826
No. of deaths 97 116 119 149
Median follow-up time (yr) 7.9 7.8 7.8 7.5
Model 1 1.00 (reference) 1.18 (0.89, 1.55) 1.26 (0.96, 1.66) 1.68 (1.29, 2.17) 0.001
Model 2 1.00 1.07 (0.80, 1.41) 1.18 (0.90, 1.55) 1.62 (1.24, 2.11) 0.001
Model 3 1.00 1.07 (0.76, 1.34) 1.14 (0.86, 1.50) 1.44 (1.09, 1.91) 0.02
Model 4 1.00 1.05 (0.78, 1.43) 1.19 (0.88, 1.60) 1.41 (1.04, 1.06) 0.10
Total lymphocyte counta,b 2.13 (2.11, 2.15) 2.59 (2.58, 2.60) 2.97 (2.96, 2.99) 3.68 (3.65, 3.71)
No. of study participants at risk 826 826 826 826
No. of deaths 136 84 73 63
Median follow-up time (yr) 7.5 7.7 7.8 7.8
Model 1 1.00 (reference) 0.57 (0.43, 0.75) 0.47 (0.35, 0.63) 0.42 (0.31, 0.56) <0.001
Model 2 1.00 0.72 (0.55, 0.96) 0.61 (0.46, 0.82) 0.61 (0.44, 0.84) 0.002
Model 3 1.00 0.73 (0.55, 0.97) 0.64 (0.48, 0.87) 0.65 (0.47, 0.89) 0.009
Model 4 1.00 0.77 (0.56, 1.05) 0.71 (0.51, 0.99) 0.70 (0.50, 0.99) 0.10
Total monocyte counta 0.26 (0.25, 0.27) 0.37 (0.36, 0.37) 0.46 (0.45, 0.46) 0.64 (0.63, 0.65)
No. of study participants at risk 827 827 827 827
No. of deaths 90 109 131 153
Median follow-up time (yr) 7.2 7.1 7.0 6.7
Model 1 1.00 (reference) 1.23 (0.92, 1.63) 1.49 (1.14, 1.96) 1.85 (1.42, 2.41) <0.001
Model 2 1.00 1.15 (0.87, 1.53) 1.29 (0.98, 1.69) 1.54 (1.17, 2.01) 0.01
Model 3 1.00 1.09 (0.81, 1.46) 1.31 (0.99, 1.73) 1.43 (1.08, 1.89) 0.05
Model 4 1.00 1.07 (0.78, 1.46) 1.26 (0.94, 1.70) 1.37 (1.01, 1.84) 0.14
Total neutrophil counta 3.59 (3.56, 3.62) 4.61 (4.60, 4.63) 5.50 (5.48, 5.52) 7.31 (7.23, 7.39)
No. of study participants at risk 825 825 826 825
No. of deaths 80 116 120 165
Median follow-up time (yr) 8.0 7.7 7.6 7.5
Model 1 1.00 (reference) 1.44 (1.08, 1.93) 1.56 (1.17, 2.07) 2.33 (1.78, 3.05) <0.001
Model 2 1.00 1.38 (1.03, 1.85) 1.47 (1.10, 1.96) 2.21 (1.67, 2.92) <0.001
Model 3 1.00 1.27 (0.94, 1.71) 1.32 (0.98, 1.78) 1.96 (1.47, 2.62) <0.001
Model 4 1.00 1.26 (0.92, 1.73) 1.37 (1.00, 1.88) 1.90 (1.39, 2.60) <0.001
Monocyte/lymphocyte ratioa,b 0.14 (0.14, 0.15) 0.20 (0.20, 0.21) 0.26 (0.25, 0.26) 0.40 (0.39, 0.41)
No. of study participants at risk 824 824 824 824
No. of deaths 86 97 106 189
Median follow-up time (yr) 7.8 7.7 7.6 7.5
Model 1 1.00 (reference) 1.09 (0.82, 1.47) 1.27 (0.95, 1.68) 2.35 (1.82, 3.03) <0.001
Model 2 1.00 0.95 (0.70, 1.27) 1.01 (0.76, 1.35) 1.61 (1.23, 2.11) <0.001
Model 3 1.00 0.88 (0.65, 1.20) 0.98 (0.73, 1.32) 1.34 (1.02, 1.78) 0.008
Model 4 1.00 0.84 (0.61, 1.16) 0.97 (0.71, 1.32) 1.24 (0.92, 1.67) 0.05
Neutrophil/lymphocyte ratioa 1.33 (1.31, 1.35) 1.97 (1.96, 1.98) 2.62 (2.60, 2.63) 4.09 (4.01, 4.16)
No. of study participants at risk 825 826 826 825
No. of deaths 83 96 116 186
Median follow-up time (yr) 7.9 7.8 7.7 7.5
Model 1 1.00 (reference) 1.21 (0.90, 1.62) 1.47 (1.10, 1.95) 2.57 (1.98, 3.33) <0.001
Model 2 1.00 1.13 (0.84, 1.53) 1.30 (0.98, 1.73) 1.95 (1.49, 2.56) <0.001
Model 3 1.00 1.11 (0.82, 1.50) 1.16 (0.87, 1.56) 1.74 (1.32, 2.31) 0.008
Model 4 1.00 1.13 (0.82, 1.56) 1.20 (0.88, 1.63) 1.68 (1.24, 2.27) 0.003
Model 1 was unadjusted. Model 2 adjusted for age, sex, body mass index, smoking and high-sensitivity C-reactive protein. Model 3 additionally adjusted for dyslipidaemia,
type 2 diabetes mellitus, resting heart rate, systolic and diastolic blood pressure, hypertension, clinical indication of coronary angiography, angina pectoris, atrial ﬁbrillation,
family history of cardiovascular disease, symptoms of heart failure, coronary angioplasty, and cardiovascular treatment (i.e., ACE-inhibitors, angiotensin receptor blockers, b-
blockers, statins and aspirin). Model 4 also excluded patients reporting a current infection.
a Values are geometric means (95% conﬁdence interval), 103/ml.
b Lymphocte count did not include CD16/CD56 sub-population. WBC¼white blood cell.
B. ó Hartaigh et al. / Atherosclerosis 224 (2012) 161e169166genome-wide signiﬁcant loci associated with CRP levels conﬁrmed
there was no evidence to indicate that variations in these genetic
loci explained the association between CRP and CHD [26]. In that
study, neither the individual single nucleotide polymorphisms nor
their combined genetic risk score were signiﬁcantly related to the
risk of MI and CHD [26]. In agreement, a separate report by Elliot
and colleagues [27] indicated that genetically elevated CRP was
not found to be associated with risk of clinical events due to MI
and CHD. Collectively, it seems the lack of concordance in support
of CRP genotypes and CRP levels towards the risk of CVD would
argue against a causal role for CRP in CVD. On the other hand, theincremental adjustments did not affect the HR seen for neutro-
phils. Thus, the present observation and those of others indicate
that the neutrophil count, which can be assessed reliably and
inexpensively, may well be a more useful and relevant predictor of
CVD risk in clinical practise [6,7,28e33].
Though perhaps not yet conclusive, compelling evidence does
suggest a causal role for neutrophils in atherosclerosis [34,35],
consistent with the current study observation that the HR
remained unperturbed by multiple adjustments, including the
inﬂammatory marker CRP. Neutrophils trafﬁc to inﬂamed arteries
where their short lifespan is extended by inﬂammatory cytokines
Table 3
Hazard ratios (quartile 4 vs quartile 1) for the prediction of cardiovascular mortality
according to subset compartments.
Univariable analysis Multivariable analysis
HR 95% CI P HR 95% CI P
Lymphocyte subsets
CD3 cells 0.60 0.46e0.80 <0.001 0.85 0.61e1.18 0.32
CD4 cells 0.55 0.41e0.74 <0.001 0.76 0.54e1.07 0.12
CD8 cells 0.83 0.62e1.10 0.19
CD4:CD8 ratio 0.84 0.63e1.12 0.23
CD19 cells 0.44 0.32e0.60 <0.001 0.76 0.54e1.09 0.13
Monocyte subsets
CD11b cells 1.03 0.80e1.33 0.80
CD18 cells 1.05 0.81e1.38 0.67
CD31 cells 1.18 0.90e1.54 0.23
CD40 cells 1.02 0.78e1.33 0.89
CD58 cells 1.34 1.03e1.73 0.03 0.98 0.73e1.32 0.90
Neutrophil subsets
CD11b cells 1.28 0.93e1.74 0.13
CD18 cells 1.26 0.94e1.69 0.13
CD31 cells 0.73 0.54e0.99 0.04 0.78 0.56e1.10 0.16
CD40 cells 1.11 0.88e1.41 0.38
CD58 cells 1.19 0.90e1.57 0.22
Multivariable analysis was adjusted as abbreviated in Table 2.
Table 4
Hazard ratios derived from a multivariable backward regression model using
competing risks for the association of various conventional risk factors with
cardiovascular mortality.
Variable HR 95% CI P
Age 1.03 1.02e1.05 <0.001
Female sex 0.78 0.62e0.98 0.04
Type 2 diabetes mellitus 1.50 1.19e1.89 0.001
Diastolic blood pressure 0.99 0.97e1.00 0.01
Atrial ﬁbrillation 1.52 1.17e1.97 0.002
Angina pectoris
Stable 0.63 0.50e0.80 <0.001
Unstable 0.46 0.35e0.60 <0.001
New York Heart Association
functional class
1 1.00 reference
2 1.18 0.94e1.47 0.15
3 1.44 1.11e1.86 0.006
4 1.77 1.06e2.96 0.03
Diseased vessels
0 1.00 reference
1 1.26 0.92e1.73 0.14
2 1.39 1.02e1.90 0.04
3 1.55 1.16e2.06 0.003
Aspirin 1.22 1.17e2.40 <0.001
ARBs 1.10 1.01e1.98 0.03
b-blockers 0.80 0.65e0.99 0.04
Neutrophils 1.21 1.10e1.34 <0.001
The model initially included age, sex, body mass index, smoking, high-sensitivity C-
reactive protein, dyslipidaemia, type 2 diabetes mellitus, resting heart rate, systolic
and diastolic blood pressure, hypertension, clinical indication of coronary angiog-
raphy, atrial ﬁbrillation, angina pectoris, family history of cardiovascular disease,
symptoms of heart failure, coronary angioplasty, ACE-inhibitors, angiotensin
receptor blockers, b-blockers, statins and aspirin, and the neutrophil count. Reten-
tion criteria was P< 0.05. ARB¼ angiotensin receptor blocker.
B. ó Hartaigh et al. / Atherosclerosis 224 (2012) 161e169 167and there they further promote vascular inﬂammation and plaque
instability. The mechanisms by which neutrophils promote plaque
instability are still under investigation but include the release of
reactive oxygen species, myeloperoxidase, proteolytic enzymes,
and arachidonic acid metabolites [4,5,7]. Recently studies in
patients with ACS have suggested that neutrophil elastase
promotes CD163 shedding from macrophages, leading to
a decreased clearance of haemoglobin by macrophages, which
may in turn favour plaque destabilization [36]. Neutrophils also
swiftly inﬁltrate the luminal-plaque regions, residing near the
ﬁbrous cap [34,35,37]. In response to inﬂammation, neutrophils
become more rigid, obstructing small nutrient vessels which may
promote myocardial ischemia/infarction [38e40]. On the back-
ground of these observations, it is somewhat surprising, therefore,
that neutrophils have not been more thoroughly investigated in
the context of atherogenesis. This may, perhaps, be a consequence
of their sparse presence during the development of humanFig. 2. Mutually adjusted hazard ratios (quartile 4 vs quartile 1) for the risk of
cardiovascular mortality according to baseline neutrophil (N) count and high sensi-
tivity C-reactive protein (CRP). Model 1 was unadjusted. Model 2 corrected for age, sex,
body mass index, smoking, lipids, type 2 diabetes mellitus, resting heart rate, systolic
and diastolic blood pressure, hypertension, clinical indication of coronary angiography,
angina pectoris, atrial ﬁbrillation, family history of cardiovascular disease, symptoms of
heart failure, coronary angioplasty, and cardiovascular medication. In Model 3, patients
with a current infection were removed.atherosclerotic lesions, suggesting a less important role [4,35].
Nonetheless, their low presence may be misleading, and can, at
least in part, be explained by the short lifespan of neutrophils,
recently estimated at 5.4 days [41], which following recruitment to
an area of inﬂammation will eventually undergo apoptosis.
Further, local macrophages rapidly phagocytose both apoptosing
and intact neutrophils [42], the latter phenomenon occurring in
activated neutrophils and mediated via externalisation of phos-
phatidylserine during neutrophil activation [43] and possibly also
involving galectins in promoting subsequent uptake by macro-
phages [44]. The local destruction of neutrophils appears func-
tional, however, and enhances the antimicrobial capacity of
macrophages through the acquisition and use of neutrophil
microbicidal molecules. Thus, while there is good evidence to
support a causal role for a raised peripheral neutrophil count in
the development of cardiovascular disease, paradoxically their
potent role evolves, in part, from cellular processes whereby the
evidence for their involvement is being destroyed.
Several limitations of our study bear mentioning. Though
prospective in patient enrollment, total and differential WBC
parameters were determined at a single time point, and therefore,
are cross-sectional in nature. Subjects in the present study were
Caucasian of German ancestry referred for coronary angiography.
Thus, caution is warranted when transferring our ﬁndings towards
the understanding of atherosclerosis in other populations.
Although we performed multivariable adjustments, we cannot
rule out that our results may be inﬂuenced by unmeasured or
unknown confounders. Due to the large sample size and extensive
range of measurements taken, we were however, able to adjust for
a range of important confounders which may, in part, address this
issue. The associations of neutrophil, monocyte, and lymphocyte
sub-compartments with CVD mortality no longer retained their
signiﬁcance after correcting for a range of potential confounders.
Fig. 3. C-index derived from receiver operating characteristic (ROC) analysis for the
prediction of cardiovascular mortality. Base model (gray) includes age, sex, type 2
diabetes mellitus, diastolic blood pressure, atrial ﬁbrillation, angina pectoris, New York
Heart Association functional class, number of diseased vessels, aspirin, ARBs and b-
blockers; Model 2 (black) additionally includes neutrophils.
Fig. 4. Proportion of observed and predicted cases according to the risk model that
included the neutrophil count. HosmereLemeshow test for goodness-of-ﬁt indicated
no signiﬁcant deviation between observed and predicted risk (P¼ 0.47).
B. ó Hartaigh et al. / Atherosclerosis 224 (2012) 161e169168Despite these ﬁndings, we cannot exclude the possibility that
other functionally distinct subsets may be implicated in the
process of atherosclerosis, that weren’t examined here. For
example, within the monocyte compartment, a minor subset
(<15% of monocytes) has been identiﬁed that may account for 90%
of monocyte TNF-alpha production and may contribute to athe-
roprogression as observed in preclinical studies [45,46]. Clearly,
further investigations to dissect the involvement of other func-
tionally distinct cell phenotypes in the initiation, progression and/
or development of atherosclerotic-related complications are
necessary [11].
In summary, a simple, inexpensive, and readily available marker
of inﬂammation, the neutrophil count should be considered as the
mainstay among leukocytes for CVD prediction in a high-risk
population. Further understanding of a high neutrophil count in
combination with other markers of inﬂammation or simulta-
neously within a multiple-marker setting may provide clinically
useful incremental information.Table 5
Reclassiﬁcation of intermediate (deﬁned as 6e20%) risk patients with and without
the cardiovascular endpoint.
Classiﬁcation according to
conventional risk factors
Reclassiﬁcation accounting for
neutrophils
Low Intermediate High Total no.
Patients with CVD endpoint
Low <6% in 10 yrs 28 6 0 34
Intermediate 6e20% in 10 yrs 6 137 24 167
High >20% in 10 yrs 0 13 208 221
Total no. with event 34 156 232 422
Patients without CVD endpoint
Low <6% in 10 yrs 937 91 0 1028
Intermediate 6e20% in 10 yrs 163 1076 65 1,304
High >20% in 10 yrs 0 70 369 439
Total no. without event 1100 1237 434 2771
Net reclassiﬁcation improvement 5.0% (P¼ 0.003)
Conventional risk factor model included age, sex, type 2 diabetes mellitus, diastolic
blood pressure, atrial ﬁbrillation, angina pectoris, New York Heart Association
functional class, number of diseased vessels, aspirin, ARBs and b-blockers.Conﬂict of interest
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